Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.73 |
| ▸ | MMP1 | P03956 | 8/20 | 0.73 |
| ▸ | MMP12 | P39900 | 2/20 | 0.73 |
| ▸ | MMP13 | P45452 | 2/20 | 0.73 |
| ▸ | MMP9 | P14780 | 7/20 | 0.57 |
| ▸ | MMP3 | P08254 | 6/20 | 0.57 |
| ▸ | MMP8 | P22894 | 5/20 | 0.57 |
| ▸ | MMP7 | P09237 | 3/20 | 0.57 |
| ▸ | FCER2 | P06734 | 2/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.49 |
| ▸ | IL1RN | P18510 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633155 | 0.88 | MMP2 (0.81) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL27547968 | 0.88 | MMP2 (0.81) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL27573505 | 0.87 | MMP1 (0.70) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634107 | 0.87 | MMP1 (0.70) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634106 | 0.87 | MMP1 (0.70) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL29838142 | 0.84 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634577 | 0.84 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634587 | 0.84 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634581 | 0.84 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4635129 | 0.80 | MMP2 (0.76) | MMP2MMP1MMP12MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION | 2012-05-10 | — | — | US | disclosed |
| WO-2010062628-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GJB2, GPR180 | MMP2 3607/4885MMP1 1996/4885MMP12 3142/4885 |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | CHRM3, CHRNG, GRK3 | MMP2 2528/4885MMP1 1698/4885MMP12 2446/4885 |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | CFTR, GJB2, KRAS | MMP2 2983/4885MMP1 748/4885MMP12 2326/4885 |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | MMP9, MMP14, MMP10 | MMP2 11/4885MMP1 12/4885MMP12 9/4885 |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | RGS17, RGS16, CHRM3 | MMP2 2273/4885MMP1 1856/4885MMP12 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.